Sapience Therapeutics, Inc.

Tarrytown, NY

UEI
ERRLJEYAUMC8
CAGE
7TRJ2
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
520 White Plains Rd Suite 2, Tarrytown, NY 10591, USA
Founded
2015
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for WNT-driven breast… R44CA265503 National Cancer Institute (NIH) $4,718,915
Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for WNT-driven breast… R43CA265503 National Cancer Institute (NIH) $1,227,885
Inhibition of sars-COV-2 infection with a pan-coronavirus anti-viral peptide R43AI157521 National Institute of Allergy and Infectious Diseases (NIH) $1,131,832
Efficacy and PK/PD of a c/EBP beta antagonist in orthotopic breast cancer R44CA250786 National Cancer Institute (NIH) $2,066,693
Efficacy and PK/PD of a c/EBP beta antagonist in orthotopic breast cancer R43CA250786 National Cancer Institute (NIH) $255,240

Similar vendors

Vendor Location Primary NAICS
JPT Peptide Technologies GMBH UEI MXL9VASUBCN8 Berlin, BE 325414 Biological Product (except Diagnostic) Manufacturing
Eldec Pharmaceuticals, Inc. UEI LJBWLKDBEM17 Durham, NC 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Quercus Molecular Design, LLC UEI ZHH5N3KV48A5 Avon, CT 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Creative Biotherapeutics LLC UEI YNJ8ST14PBD8 Gurnee, IL —
Oncotrap Inc. UEI KX22VNNMBYZ3 Chapel Hill, NC 541714 Research and Development in Biotechnology (except Nanobiotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Sapience Therapeutics, Inc. is a for-profit corporate entity that provides therapeutic and diagnostic solutions to the federal government through research and development federal grants, focused primarily in the areas of oncology and infectious disease. Sapience Therapeutics specializes in the development of peptide-based therapeutics targeting intracellular protein-protein interactions.

Through prime federal grants from the National Institutes of Health, Sapience Therapeutics has conducted research and development of peptide antagonists for cancer and antiviral applications. This includes the development of a β-catenin antagonist peptide for triple negative breast cancer, funded by the National Cancer Institute (awards totaling $2.7M and $1.2M); an antiviral peptide therapeutic for SARS-CoV2 infection, funded by the National Institute of Allergy and Infectious Diseases ($1.1M); and a C/EBPβ antagonist peptide for late stage and metastatic breast cancer, also funded by the National Cancer Institute (awards of $2M and $255k). Additionally, Sapience Therapeutics has provided infectious disease research and development services as a subcontractor under federal grants.

Quick answers

Is Sapience Therapeutics, Inc. registered in SAM.gov?

Yes. Sapience Therapeutics, Inc.'s SAM.gov registration is active through March 3, 2027.

What is Sapience Therapeutics, Inc.'s most recent federal award?

Sapience Therapeutics, Inc.'s most recent federal grant award is Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for WNT-driven breast… (R44CA265503), from National Cancer Institute (NIH), on September 2, 2021.

On GovTribe

See Sapience Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login